Michael E. Carney

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Cross-listing and foreign direct investment: an institutional arbitrage perspective on Chinese multinational enterprises

  Multinational Business Review · 2025-12-08

• Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i> -deficient tubo-ovarian high-grade serous carcinomaPreprint

  medRxiv · 2025-09-22

• Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab As First-Line Treatment For Endometrial Cancer: Patient-Reported Outcomes In The DUO-E/GOG-3041/ENGOT-EN10 Intent-To-Treat And Mismatch Repair Deficient Populations

  International Journal of Gynecological Cancer · 2025-02-01 · 1 citations

• Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer

  Journal of Clinical Investigation · 2024-10-29 · 19 citations

• Supplementary Figure S2 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaPreprint

  2024-08-15

• Supplementary Figure S10 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaPreprint

  2024-08-15

• Supplementary Figure S5 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaPreprint

  2024-08-15

• Supplementary Figure S6 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaPreprint

  2024-08-15

• Supplementary Table S2 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

  2024-08-15

• Figure 3 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaPreprint

  2024-08-15

• Figure 4 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaPreprint

  2024-08-15

• Supplementary Table S1 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

  2024-08-15

• Supplementary Table S8 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

  2024-08-15

• Supplementary Figure S6 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaPreprint

  2024-08-15

• Supplementary Table S13 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

  2024-08-15

• Figure 2 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaPreprint

  2024-08-15

• Supplementary Table S17 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

  2024-08-15

• Supplementary Figure S7 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaPreprint

  2024-08-15

• Supplementary Table S12 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

  2024-08-15

• Supplementary Table S2 from Concurrent RB1 Loss and &lt;i&gt;BRCA&lt;/i&gt; Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

  2024-08-15